
2024 No. 37
Dangerous Drugs
The Misuse of Drugs (Designation) (Amendment) Order (Northern Ireland) 2024
Made 6th March 2024
Coming into operation 27th March 2024
The Department of Health, makes the following Order in exercise of the powers conferred by section 7(4) and (5) of the Misuse of Drugs Act 1971 as adapted by section 7(9) of that Act and now vested in it and after consultation with the Advisory Council on the Misuse of Drugs in accordance with section 7(7) of that Act.
Citation, commencement and interpretation
1 

(1) This Order may be cited as the Misuse of Drugs (Designation) (Amendment) Order (Northern Ireland) 2024 and shall come into operation on 27th March 2024.
(2) The Interpretation Act (Northern Ireland) 1954 shall apply to this Order as it applies to an Act of the Northern Ireland Assembly.
Amendment of the Misuse of Drugs (Designation) Order (Northern Ireland) 2001
2 

(1) The following amendments are made to Part 1 of Schedule 1 to the Misuse of Drugs (Designation) Order (Northern Ireland) 2001 (which specifies Controlled Drugs to which section 7(4) of the Misuse of Drugs Act 1971 applies).
(2) In paragraph 1(a) —
(a) after “Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)” insert “Brorphine”;
(b) after “1,4-Butanediol” insert “Butonitazene”;
(c) after “Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)” insert “Clonitazene”;
(d) after “Concentrate of poppy-straw” insert “Cumyl-PeGaClone”;
(e) after “Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)” insert—“DiphenidineEphenidineEthyleneoxynitazene”;
(f) after “Etizolam” insert—“Etodesnitazene (etazene)Etonitazene”;
(g) after “Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)” insert “Flunitazene”;
(h) after “Isopropylphenidate (IPP or IPPD)” insert “Isotonitazene”;
(i) after “Methcathinone” insert “Methoxyphenidine”;
(j) after “Metizolam (4-(2-Chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)” insert—“Metodesnitazene (metazene)Metonitazene”;
(k) after “Propylphenidate” insert “Protonitazene”;
(l) after “1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45)” insert—“N-Desethyl etonitazeneN-DesethylisotonitazeneN-Desethyl protonitazene”;
(m) after “4-Methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4’-DMAR)” insert—“N-Piperidinyl-etonitazene (etonitazepipne)N-Pyrrolidino-etonitazene (etoniazepyne)N-Pyrrolidino protonitazene”.
Sealed with the Official Seal of the Department of Health on 6th March 2024.
(L.S.)Cathy Harrison
A senior officer of the Department of Health
